Because promising results begin to emerge from initial studies regarding physiological responses which resemble those observed in CR (e.g. reduced plasma insulin), the insulin-sensitizing biguanide metformin begins to be catalogued as a CRM more than fifteen years after its launch for the treatment of type 2 diabetes. Here, INS is linked to type 2 diabetes mellitus.